Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
personalized neoantigen-pulsed autologous dendritic cell injections
- Development stage
- Phase 1
- Lead developer
- ZSky Biotech
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Personalized neoantigen-pulsed autologous dendritic cell injections (specifically ZSNeo-DC) represent an individualized cancer immunotherapy developed by ZSky Biotech. The process involves harvesting a patient's own dendritic cells and pulsing them ex vivo with a selection of neoantigens—mutated peptides identified through genomic sequencing of the patient's specific tumor. These loaded dendritic cells are then administered subcutaneously to the patient, where they act as professional antigen-presenting cells to prime and expand neoantigen-specific T cells. This approach aims to overcome the limitations of traditional vaccines by targeting unique mutations that are not subject to central tolerance, thereby inducing a potent and specific anti-tumor immune response. ZSNeo-DC is currently being evaluated in clinical studies for various malignant solid tumors, both as a monotherapy and in combination with immune checkpoint inhibitors.
- Other names
- Personalized neoantigen-pulsed autologous dendritic cell injections
02
Targets
MHC I (MHC class I})Neoantigen-specific T-cell receptorpMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on personalized neoantigen-pulsed autologous dendritic cell injections.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on personalized neoantigen-pulsed autologous dendritic cell injections.